MedTrace Logo

Immunogenicity and Safety Study of NBP606 in Healthy Toddlers

NCT02927444 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 462

Last updated 2020-04-20

No results posted yet for this study

Summary

This study will assess the immunogenicity and safety of booster vaccination with NBP606 compared to the existing commercial vaccine, when given concomitantly with routine pediatric vaccinations.

Conditions

  • Pneumococcal Infections

Interventions

BIOLOGICAL

NBP606

A single intramuscular injection into the thigh

BIOLOGICAL

Prevnar13

A single intramuscular injection into the thigh

Sponsors & Collaborators

  • SK Chemicals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
15 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-04
Primary Completion
2017-10-26
Completion
2017-10-26

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02927444 on ClinicalTrials.gov